The Role of DLBS1033 in the Management of Acute Ischemic Stroke Patients: Study Protocol for a Randomized Controlled Study
试验速览
- 阶段
- 2 期
- 入组人数
- 180
- 试验地点
- 1
- 主要终点
- Improvement in Barthel Index (BI) scores at 30 days
研究概览
简要总结
Stroke is one of the most common non-communicable diseases worldwide. It is the leading cause of morbidity and mortality in many countries.
Stroke is broadly classified into ischemic and hemorrhagic stroke. Ischemic stroke is more common than hemorrhagic stroke. In Indonesia, the prevalence of ischemic stroke is 42.9% compare to hemorrhagic stroke 19.9%. Ischemic stroke defined as an episode of neurological dysfunction caused by focal cerebral, spinal, or retinal infarction.
One of the main therapy in ischemic stroke is administration of anti thrombotic agent. DLBS1033 is a bioactive protein fraction isolated from Lumbricus rubellus. DLBS1033 possessed quadruple activities that inhibit platelet aggregation, induces fibrinogenolysis, fibrinolysis, and thrombolysis. This is a new proposed medication nowadays. There is still a limited study about DLBS1033. To our knowledge, research concern on the usage of DLBS1033 in stroke patients is very limited in Indonesia. This study aimed to Measure the benefit of DLBS1033 as add on therapy for ischemic stroke patients.
The hypothesis of this study :
a. The use of DLBS1033 improve functional status of ischemic stroke patients at hospital discharge. b. The use of DLBS1033 improve functional status 30-days after stroke onset.
详细描述
This was randomized, controlled, open-label, study from the period of April 2020 - August 2020 at Bethesda Hospital, Yogyakarta, Indonesia.
There were 180 acute ischemic stroke patients who fulfilled the inclusion and exclusion criteria. Each subject recruited from acute stroke intensive care unit had been followed up from the first day they were hospitalized until hospital discharge (died or discharged alive) and 30 days after the onset.
Ethical approval number 1087/C.16/FK/2019 was obtained from Health Research Ethics Committee, Faculty of Medicine Duta Wacana Christian University Yogyakarta. This research has been registered at Center for Health Resources and Services Research and Development Indonesia with the ethical approval number of 1087/C.16/FK/2019.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- None
盲法说明
Open label
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female
- •Adult age (>18 years old)
- •Diagnosed with acute ischemic stroke for the first time
- •The onset is <24 hours
- •Not a referral patient
- •GCS score of 15 (fully alert)
- •Mild to moderate scores on NIHSS
排除标准
- •Subjects known to have hypersensitivity to DLBS1033
- •Participated in other studies for the past 1 month
- •Not competent enough in giving approval and answering questionnaires
研究组 & 干预措施
Experimental Group
standard therapy consists of aspirin 100 mg once daily, atorvastatin 20 mg once daily, vitamin B12 100 mg three times daily and DLBS1033 3 times daily (experimental group).
干预措施: DLBS1033 (Drug)
Experimental Group
standard therapy consists of aspirin 100 mg once daily, atorvastatin 20 mg once daily, vitamin B12 100 mg three times daily and DLBS1033 3 times daily (experimental group).
干预措施: Aspirin (Drug)
Experimental Group
standard therapy consists of aspirin 100 mg once daily, atorvastatin 20 mg once daily, vitamin B12 100 mg three times daily and DLBS1033 3 times daily (experimental group).
干预措施: Statin (Drug)
Experimental Group
standard therapy consists of aspirin 100 mg once daily, atorvastatin 20 mg once daily, vitamin B12 100 mg three times daily and DLBS1033 3 times daily (experimental group).
干预措施: Vit B12 (Drug)
Control Group
standard therapy consists of aspirin 100 mg once daily, atorvastatin 20 mg once daily, vitamin B12 100 mg three times daily
干预措施: Aspirin (Drug)
Control Group
standard therapy consists of aspirin 100 mg once daily, atorvastatin 20 mg once daily, vitamin B12 100 mg three times daily
干预措施: Statin (Drug)
Control Group
standard therapy consists of aspirin 100 mg once daily, atorvastatin 20 mg once daily, vitamin B12 100 mg three times daily
干预措施: Vit B12 (Drug)
结局指标
主要结局
Improvement in Barthel Index (BI) scores at 30 days
时间窗: 30 days after treatment initiation
Change in functional outcomes as measured by Barthel Index (BI) from its hospital discharge value.
Improvement in modified Rankin Scale (mRS) scores at hospital discharge
时间窗: At hospital discharge (approximately 4 days after treatment initiation)
Change in functional outcomes as measured by Modified Rankin Scale (MRS) from its baseline value.
Improvement in modified Rankin Scale (mRS) scores at 30 days
时间窗: 30 days after treatment initiation
Change in functional outcomes as measured by Modified Rankin Scale (MRS) from its hospital discharge value.
Improvement in National Institutes of Health Stroke Scale (NIHSS) scores at hospital discharge
时间窗: At hospital discharge (approximately 4 days after treatment initiation)
Change in functional outcomes as measured by National Institutes of Health Stroke Scale (NIHSS) from its baseline value.
Improvement in National Institutes of Health Stroke Scale (NIHSS) scores at 30 days
时间窗: 30 days after treatment initiation
Change in functional outcomes as measured by National Institutes of Health Stroke Scale (NIHSS) from its hospital discharge value.
Improvement in Barthel Index (BI) scores at hospital discharge
时间窗: At hospital discharge (approximately 4 days after treatment initiation)
Change in functional outcomes as measured by Barthel Index (BI) from its baseline value.
次要结局
未报告次要终点
研究者
Rizaldy Taslim Pinzon
Principal investigator, Neurologist
Duta Wacana Christian University